SIRT1 and depressive symptom measurement: To further validate the signaling pathway of luteolin for dry eye depression co-morbidity, we used the Sirt1 inhibitor EX-527 to inhibit Sirt1 protein expression levels, which reversed the ameliorative effects of luteolin on depression-like behavior, cognitive impairment, and dry eye disease symptoms in mice.